Breaking News

Bain Capital to Acquire Mitsubishi Tanabe Pharma Corporation

Tanabe Pharma to benefit from the full support of Bain Capital’s global resources and its healthcare team.

Author Image

By: Charlie Sternberg

Associate Editor

Image courtesy of Konstantin Kolosov from Pixabay.

Bain Capital, a global private investment firm, has signed a definitive agreement to acquire Mitsubishi Tanabe Pharma Corporation (MTPC) from Mitsubishi Chemical Group Corporation. The investment values the business at approximately $3.3 billion. Through the discovery and development of innovative drugs that address unmet medical needs, MTPC focuses on several priority therapeutic areas, including immunology & inflammation, vaccines, central nervous system (CNS), diabetes and metabolic di...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters